No Data
No Data
No Data
No Data
No Data
Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Elicio Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMay 1 18:36
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $11 to $10.
BenzingaMay 1 18:25
HC Wainwright & Co. : The Elicio Therapeutics (ELTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $11.00 to $10.00.
HC Wainwright & Co. : The Elicio Therapeutics (ELTX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $11.00 to $10.00.
Zhitong FinanceMay 1 18:20
Elicio Therapeutics to Present New Preliminary Data From the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients With MKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the
GlobeNewswireApr 25 20:30
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies
ProdigyPressApr 25 00:20
Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO Is the Most Bullish Insider, and Their Stock Value Gained 11%last Week
Yahoo FinanceApr 13 21:19
No Data
No Data